People
Liquidia Technologiesnlaunched a successful initial public offering on July 25, raising $50 million. Neal Fowler, the company’s chief executive officer, and Kevin Gordon, Liquidia’s president and chief financial officer, took time out to talk with BioSpace about the company and where it’s headed.
Two of Amgen’s executive vice presidents are leaving the company.
Achaogen, headquartered in South San Francisco, announced that as part of its strategic update and corporate restructuring, it will eliminate 80 positions, or about 28 percent of staff.
Gilead Sciences’ president and chief executive officer, John Milligan, is retiring after 28 years with the company. Gilead is beginning a search for a replacement.
If there’s one thing that defines the tenure of FDA Commissioner Scott Gottlieb, it is his outspoken mission to lower drug prices by introducing more competition into the biopharmaceutical market. And a big part of that mission has been doing what he can to boost the nascent biosimilar industry.
Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.
After spending 14 years behind bars for sexually molesting a 10-year-old girl, famed geneticist W. French Anderson was shocked to see the leaps and bounds made by scientists in his field when he emerged from prison.
Nearly four months after acquiring 100 percent control of its consumer health unit, GlaxoSmithKline Chairman Philip Hampton may be pushing for the business to become a standalone entity apart from its pharma and vaccines division, according to The Financial Times.
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.
PRESS RELEASES